Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Malignant Mesothelioma
Interventions: recombinant interferon gamma, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, mitomycin C, conventional surgery, hyperthermia treatment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Neoplasms, Neoplasm Metastasis, Hepatic Neoplasms
Interventions: Microwave ablation, Hepatic resection; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab; Drug · Biological · Procedure + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Goodyear, Arizona • Corona, California • Duarte, California + 10 more

Conditions: Bladder Cancer
Interventions: Everolimus and Intravesical Gemcitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Anesthesiology, Pediatrics, General Surgery, Orthopedics, General Anesthesia, Cardiac Output
Interventions: Bilateral cardiac output; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Month to 8 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin Disease
Interventions: Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Semilunar Heart Valve Replacement
Interventions: Partial Heart Transplantation; Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Day to 2 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV
Interventions: Information, motivation, behavioral skills treatment arm, Information only control arm; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 19 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pregnancy Complications, Acute Appendicitis, Acute Cholecystitis, Biliary Pancreatitis, Bowel Obstruction, Acute Diverticulitis
Interventions: non-obstetric acute general surgical disease; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19, Sleep, Immunization; Infection, Physical Inactivity, Blood Pressure, Diet Habit, Mental Health Wellness 1
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Lymphoma
Interventions: rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 2
States / cities: Los Angeles, California • Omaha, Nebraska

Conditions: Lymphoma, Lymphoma, Large B-Cell, Diffuse
Interventions: Glofitamab, Polatuzumab, Rituximab, Doxorubicin Hydrochloride, Cyclophosphamide, Prednisone; Drug
Lead sponsor: Jennifer Crombie, MD; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts

Conditions: Prostate Cancer, Robotic Prostatectomy, Foley Catheter Discomfort
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma
Interventions: Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin with a Taxane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 54
States / cities: Mobile, Alabama • Tucson, Arizona • Bakersfield, California + 49 more

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab soravtansine, Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Boston, Massachusetts • Reno, Nevada + 3 more

Conditions: Breast Neoplasm
Interventions: Paclitaxel, Doxorubicin, Cyclophosphamide, G-CSF; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Lymphoblastic Leukemia
Interventions: Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more

Conditions: Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Interventions: stellate ganglion block with 0.5% bupivacaine; Drug
Lead sponsor: Jonathann Kuo, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia
Interventions: Metformin, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Intrathecal chemotherapy; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 1 Year to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • St. Petersburg, Florida + 2 more

Conditions: Major Depressive Disorder, Bipolar Depression
Interventions: Xenon, Nitrogen gas; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Interventions: Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Atlanta, Georgia • Madison, Wisconsin

Conditions: HIV
Interventions: Thrive With Me Control, Thrive With Me Intervention; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Intraocular Pressure, Oncology
Interventions: TIVA, Balanced anesthesia; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sleep
Interventions: The Calm app; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

A Prospective Study to Bilaterally Compare a Non-Invasive Cardiac Output Monitor

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Partial Heart Transplantation for Severe Pediatric Semilunar Valve Dysfunction

Effectiveness and Implementation of Text Messaging to Improve HIV Testing in Adolescents

Fetal Outcomes Among Pregnant Emergency General Surgery Patients

COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12

ALL Adult Consortium Trial: Adult ALL Trial

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults

Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients

Calm + Oura Sleep Study